Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01542684 · ClinicalTrials.gov registry record · Phase 2
Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01542684: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01542684 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01542684, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if the combination of azacitidine and GM-CSF can help to control MDS. The safety of these drugs will also be studied. Azacitidine is designed to block certain proteins that stop the function of tumor-fighting genes. By blocking the "bad" proteins, the tumor-fighting genes may be able to work better. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is designed to help produce white blood cells. This may help to fight infections.
Interventions
- DRUG Azacytidine
- DRUG GM-CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01542684
The ClinicalTrials.gov registry entry for NCT01542684 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azacytidine is the first listed.
NCT01542684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01542684 about?
NCT01542684 is a clinical study titled "Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)". The goal of this clinical research study is to learn if the combination of azacitidine and GM-CSF can help to control MDS. The safety of these drugs will also be studied. Azacitidine is designed to block certain proteins that stop the function of tumor-fighting genes. By blocking the "bad" proteins...
What is the current status of trial NCT01542684?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2012-03. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01542684?
The interventions under investigation include: Azacytidine (DRUG), GM-CSF (DRUG).
Who is sponsoring clinical trial NCT01542684?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.